Zealthy review

What it is

Zealthy is a membership telehealth service for weight loss, primary care and other needs, based in New York [17]. Its weight-loss program pairs a provider with a coach and an insurance coordination team, and the medicine is billed separately from the membership [5]. FDA sent the company behind it, FitRX, LLC doing business as Zealthy, a warning letter in September 2025 [16].

What it prescribes

Both kinds. Zealthy’s providers may prescribe Zepbound, Wegovy, Ozempic or Mounjaro when appropriate [1]. It also sells compounded semaglutide and tirzepatide for cash [6]. Zealthy’s own page says compounded GLP-1s are not FDA approved [2], and FDA says it does not review compounded drugs for safety, effectiveness or quality before they are sold [23]. A compounded injection is a different product from an approved pen. See our Zepbound and Wegovy pages; Ozempic and Mounjaro are approved for type 2 diabetes, as our approved uses guide explains.

What it costs

The membership is typically $135 a month [3]. Zealthy’s own pages disagree on the first month: its FAQ says $39 [4], while a pricing page says $49 after a discount of $86 [3]. The medicine is not included in the membership [5].

• Compounded semaglutide from $151 a month and compounded tirzepatide from $216 a month, shipping included [6].
• Those lowest prices assume you buy a three-month supply at once [7].
• For brand-name drugs, Zealthy’s team works with your insurance [8], and some members pay as little as a $25 monthly copay [9]. It does not post cash prices for the brand-name drugs.

Our coverage guide explains how insurers handle GLP-1s, and our savings check lists the makers’ own cash prices if your plan says no.

Where it operates

Zealthy says its services are available to eligible members in all 50 states, with some variation by state [10].

Signing up and cancelling

The membership is charged every month on the date of your first payment, and you can cancel at any time [11]. Membership, visit and consultation fees are not refunded [12], and all sales of prescription products are final [13]. Our guide to cancelling a GLP-1 program lists what to check before you leave.

Safety and regulatory record

FDA reviewed getzealthy.com in August 2025 [14]. Its warning letter objected to website claims that tied the compounded semaglutide to Wegovy and Ozempic, saying they implied the compounded drug was the same as an approved product when it is not [15]. The letter went to FitRX, LLC at the same New York address Zealthy lists today [16] [17]. A Zealthy pricing page GLPLens read in September 2026 still compared its compounded semaglutide to Ozempic and Wegovy by active ingredient [18].

FDA later sent two more warning letters to FitRX, LLC at that address, under the names FitRx in February 2026 and AM RX in June 2026 [19] [20] [21] [22]. FDA’s database listed no close-out letter for any of them when this page was updated, so we treat them as open. Because of the letters, and because it sells compounded drugs, GLPLens does not link to Zealthy.

Who it suits, and who should look elsewhere

Zealthy may suit someone with drug coverage who wants help getting a brand-name GLP-1 approved, with a compounded cash option if the insurer says no. Look elsewhere if open FDA warning letters concern you, if you want published cash prices for brand-name drugs, or if you would rather not pay a monthly membership on top of the medicine. Our programs page compares brand-name options.